| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 8.4 µM (Mtase)[1]
Benzyl selenocyanate targets DNA (cytosine-5)-methyltransferase (DNMT), an enzyme responsible for DNA methylation that plays a critical role in gene expression regulation and cancer development. By inhibiting DNMT, the compound can modulate epigenetic modifications, potentially reactivating tumor suppressor genes or silencing oncogenes. The compound may also inhibit protein kinases such as PKA and PKC. Its antimicrobial activity is attributed to its ability to disrupt essential cellular processes in bacteria, with enhanced potency compared to sulfur-containing analogs. The compound's diverse targets contribute to its chemopreventive and antimicrobial properties. |
|---|---|
| ln Vitro |
In a concentration-dependent manner, benzoyl selenocyanate suppresses the activity of DNA (cytosine-5)-methyltransferase (Mtase)[1].
In vitro studies demonstrate that benzyl selenocyanate inhibits DNA methyltransferase activity with an IC₅0 of 8.4 microM. The compound has been evaluated for its ability to inhibit tumor cell proliferation and induce apoptosis in various cancer cell lines. Its chemopreventive activity has been confirmed in cell-based assays where it reduces chemically induced malignant transformation. The compound also exhibits broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, including drug-resistant strains such as MRSA. Its antimicrobial activity is superior to that of sulfur-containing analogs, highlighting the unique properties conferred by the selenium atom. |
| ln Vivo |
In vivo studies demonstrate that benzyl selenocyanate is an effective chemopreventive agent in animal models of chemically induced tumors. The compound reduces tumor incidence and multiplicity when administered at both the initiation and post-initiation stages of carcinogenesis. Its efficacy has been demonstrated in models of various cancer types, including colon, breast, and lung cancer. The compound's mechanism of action in vivo involves inhibition of DNA methylation, modulation of cell proliferation and apoptosis, and potential antioxidant effects. Its antimicrobial efficacy has also been evaluated in animal models of infection, though these studies are less extensively reported.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for benzyl selenocyanate focus on its inhibition of DNA methyltransferase (DNMT) activity. The assay typically uses purified recombinant DNMT enzyme and a DNA substrate containing CpG sites. The reaction mixture contains the enzyme, substrate, and the methyl donor S-adenosylmethionine (SAM) in the presence or absence of the compound. After incubation, DNA methylation is quantified using radiolabeled SAM or by ELISA-based detection of methylated DNA. IC₅0 values are calculated from dose-response curves. The compound may also be tested against other enzymes such as PKA and PKC using standard kinase activity assays.
|
| Cell Assay |
Cellular assays for benzyl selenocyanate are conducted using cancer cell lines to evaluate its anti-proliferative and chemopreventive effects. Cells are treated with varying concentrations of the compound (typically 1-100 microM) for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or colony formation assays. Apoptosis is evaluated by Annexin V/PI staining, caspase activity assays, or Western blotting for apoptosis-related proteins. DNA methylation changes are assessed using bisulfite sequencing or methylation-specific PCR. Antimicrobial activity is assessed using standard broth microdilution methods to determine minimum inhibitory concentration (MIC) values against bacterial strains.
|
| Animal Protocol |
In vivo animal studies with benzyl selenocyanate are primarily conducted in rodent models of chemically induced carcinogenesis. Animals are administered the carcinogen (e.g., azoxymethane for colon cancer, DMBA for breast cancer) and then treated with benzyl selenocyanate via oral gavage or dietary administration at various doses (typically 5-50 mg/kg). Tumor incidence, multiplicity, and size are monitored over the study period. At termination, tissues are collected for histopathological analysis and molecular studies (DNA methylation, gene expression, apoptosis markers). The compound's chemopreventive efficacy is assessed by comparing tumor development in treated versus control groups.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of benzyl selenocyanate are characteristic of organoselenium compounds. The compound has a molecular weight of 196.11 g/mol and a boiling point of 276.7+/-33.0degC. It is lipophilic with a vapor pressure of 0.0+/-0.6 mmHg at 25degC. Following oral administration, the compound is absorbed and distributed to various tissues, where it may be metabolized to active selenium species. Selenium compounds are known to be incorporated into selenoproteins and excreted via urine and feces. Detailed PK parameters such as half-life, Cmax, and bioavailability are not extensively reported in the literature for this specific compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for benzyl selenocyanate are limited, though organoselenium compounds are generally known to have a narrow therapeutic window due to selenium toxicity at high doses. The compound is not intended for human therapeutic use and is supplied for research purposes only. At standard research doses (5-50 mg/kg in animal studies), the compound is generally well-tolerated, with no significant toxicity reported. However, higher doses may cause selenium-related toxicity including gastrointestinal distress, hair loss, nail changes, and neurological symptoms. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
See also: Selenocyanate (note moved to).
Benzyl selenocyanate is a chemopreventive organoselenium compound that inhibits DNA methyltransferase and demonstrates efficacy against chemically induced tumors in animal models. It also exhibits broad-spectrum antimicrobial activity superior to sulfur-containing analogs. The compound is found in selenium-enriched garlic and is used in the preparation of organoselenium derivatives for applications in medicinal chemistry, materials science, and antioxidant or catalytic studies. It is not an FDA-approved drug and has no clinical indications. The compound is available in high purity (≥98%) and is typically stored at room temperature. |
| Molecular Formula |
C8H7NSE
|
|---|---|
| Molecular Weight |
196.11
|
| Exact Mass |
196.974
|
| CAS # |
4671-93-6
|
| PubChem CID |
101450
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
276.7ºC at 760 mmHg
|
| Flash Point |
121.2ºC
|
| LogP |
1.638
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
129
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WSKWDMOVMQKKQI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H7NSe/c9-7-10-6-8-4-2-1-3-5-8/h1-5H,6H2
|
| Chemical Name |
benzyl selenocyanate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0992 mL | 25.4959 mL | 50.9918 mL | |
| 5 mM | 1.0198 mL | 5.0992 mL | 10.1984 mL | |
| 10 mM | 0.5099 mL | 2.5496 mL | 5.0992 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
